Dexcom Inc (NASDAQ:DXCM) finished Friday with a subtraction of -$2.16 to close at $93.30, a downside of -2.26 percent. An average of 5,563,580 shares of common stock have been traded in the last five days. There was a gain of $5.80 in the past week, and it reached a new high 22 times over the past 12 months. The last 20 days have seen an average of 4,763,120 shares traded, while the 50-day average volume stands at 4,273,170.
DXCM stock has decreased by -9.79% in the last month. The company shares reached their 1-month lowest point of $85.31 on 09/25/23. With the stock rallying to its 52-week high on 07/28/23, shares of the company touched a low of $80.36 and a high of $139.55 in 52 weeks. It has reached a new high 21 times so far this year and lost -17.61% or -$19.94 in price. In spite of this, the price is down -33.14% from the 52-week high.
Insider Transactions
DXCM stock investors should be aware that Dexcom Inc (DXCM) stock had its last reported insider trading activity 8 days ago on Sep 22. In this transaction, the insider spent $36,332. Director, ALTMAN STEVEN R, disposed of 1,000 shares at a price of $101.50 on Sep 15. The insider now owns more than $101,495 worth of shares. Prior to that, Director Heller Bridgette P went on to Sale 600 shares at $106.56 each on Sep 12. An amount of $63,936 was transacted.
Valuation Metrics
Dexcom Inc (DXCM) has a trailing price-to-earnings (P/E) ratio of 108.86. The stock’s beta is 1.12. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.32, the price-to-book (PB) ratio at 17.15, and the price-to-cash flow ratio at 77.66.
Financial Health
The quick ratio of Dexcom Inc for the three months ended June 29 was 2.21, and the current ratio was 2.42, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.23 and a total debt to equity ratio of 1.61 for the quarter ending June 29. Its gross profit as reported stood at $1.88 billion compared to revenue of $2.91 billion.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $115.9 million in the quarter, while revenues of $48.6 million were grew 56.08%. The analyst consensus anticipated Dexcom Inc’s latest quarter earnings to come in at $0.23 per share, but it turned out to be $0.34, a 47.80% surprise. For the quarter, EBITDA amounted to $171.8 million. Shareholders own equity worth $387.87 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Dexcom Inc (DXCM) price momentum. RSI 9-day as of the close on 29 September was 44.66%, suggesting the stock is Neutral, with historical volatility in this time frame at 43.06%.
As of today, DXCM’s price is $91.11 +6.63% or $5.80 from its 5-day moving average. DXCM is currently trading -7.61% lower than its 20-day SMA and -22.37% lower than its 100-day SMA. However, the stock’s current price level is -28.59% below the SMA50 and -20.11% below the SMA200.
The stochastic %K and %D were 36.86% and 27.44%, respectively, and the average true range (ATR) was 3.80. With the 14-day stochastic at 36.27% and the average true range at 3.87, the RSI (14) stands at 41.22%. The stock has reached 2.63 on the 9-day MACD Oscillator while the 14-day reading was at -0.82.
Analyst Ratings
The consensus rating for Dexcom Inc (DXCM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell DXCM, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 4 analysts, while 17 others rate it as a “buy”.
What is DXCM’s price target for the next 12 months?
Analysts predict a range of price targets between $98.00 and $160.00, with a median target of $150.00. Taking a look at these predictions, the average price target given by analysts for Dexcom Inc (DXCM) stock is $145.36.
